Loading
A phase 1/2 trial of AZD5863 in pancreatic ductal adenocarcinoma, run by AstraZeneca, now recruiting.
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06005493 by AstraZeneca, with 280 participants planned, started 2023-07-11 and due to reach its primary completion in 2027-07-16. Interventions recorded: AZD5863. Conditions listed: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma. No results are recorded here; the registry entry is the source.